Secretolytic therapy for acute and chronic bronchopulmonary diseases associated with violations of bronchial secretion and weakening of mucus promotion.
Flavamed 30 mg/5 ml Storage
active substance: ambroxol hydrochloride;
5 ml of oral solution contain ambroxol hydrochloride 30 mg;
excipients: benzoic acid (E 210); glycerin (85%); sorbitol solution that does not crystallize (E 420); hydroxyethylcellulose, purified water, raspberry flavor
Flavamed 30 mg/5 ml Dosage form
The solution is oral.
Main physical and chemical properties: a clear solution from colorless to slightly yellow with a fruity odor close to the smell of raspberries.
Flavamed 30 mg/5 ml Pharmacotherapeutic group
Remedies used for coughs and colds. Mucolytics. ATX code R05C B06.
The active substance of FLAVAMED® FORTE – ambroxol hydrochloride – increases the secretion of the respiratory tract. Ambroxol enhances pulmonary surfactant secretion by directly affecting type II pneumocytes in alveoli and Clara cells in bronchioles, and stimulates ciliary activity, thereby reducing mucus viscosity, mucus secretion, and excretion (improved mucociliary clearance). Improvement in mucociliary clearance has been demonstrated in clinical pharmacology studies.
Activation of fluid secretion and increased mucociliary clearance facilitate mucus excretion and reduce cough.
The local anesthetic effect of ambroxol hydrochloride is due to its sodium channel blocking properties observed in a rabbit eye model. In vitro studies have shown that ambroxol hydrochloride blocks neural sodium channels; binding was reversible and dependent on concentration.
Ambroxol hydrochloride has been shown to have anti-inflammatory effects in vitro. In vitro studies have shown that ambroxol hydrochloride significantly reduces the release of cytokines from mononuclear and polymorphonuclear cells in blood and tissues.
The pharmacological properties that lead to rapid pain relief and pain-related discomfort in the nasal cavity, ear and trachea when inhaling air are consistent with ancillary monitoring of symptoms in clinical trials of the efficacy of ambroxol hydrochloride in the treatment of the upper respiratory tract.
Concentrations of antibiotics (amoxicillin, cefuroxime, erythromycin and doxycycline) in bronchopulmonary secretion and sputum increase after administration of ambroxol hydrochloride.
Absorption. Absorption of ambroxol hydrochloride is rapid and fairly complete, with a linear dose-response in the therapeutic range. Maximum levels in blood plasma are reached in 1-2.5 hours with oral administration of rapid-release dosage forms.
Secretolytic therapy for acute and chronic bronchopulmonary diseases associated with impaired bronchial secretion and impaired mucus.
FLAVAMED® FORTE should not be used in patients with known hypersensitivity to ambroxol hydrochloride or to other components of the syrup.
In the case of rare congenital conditions, due to which intolerance of the excipient is possible (see section “Special warnings”), taking the drug is contraindicated.